Charles S Morrison

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7120442/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant. Sexually Transmitted Infections, 2021, 97, 249-255.	1.9	17
2	Aberrant cervical innate immunity predicts onset of dysbiosis and sexually transmitted infections in women of reproductive age. PLoS ONE, 2020, 15, e0224359.	2.5	20
3	Integrating oral PrEP delivery among African women in a large HIV endpointâ€driven clinical trial. Journal of the International AIDS Society, 2020, 23, e25491.	3.0	18
4	Comparison of pregnancy incidence among African women in a randomized trial of intramuscular depot medroxyprogesterone acetate (DMPA-IM), a copper intrauterine device (IUDs) or a levonorgestrel (LNG) implant for contraception. Contraception: X, 2020, 2, 100026.	1.8	1
5	HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet, The, 2019, 394, 303-313.	13.7	230
6	Comprehensive Profiling of HIV Antibody Evolution. Cell Reports, 2019, 27, 1422-1433.e4.	6.4	27
7	Identification and validation of a multiâ€assay algorithm for crossâ€sectional HIV incidence estimation in populations with subtype C infection. Journal of the International AIDS Society, 2018, 21, e25082.	3.0	26
8	Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies. PLoS Medicine, 2018, 15, e1002511.	8.4	158
9	Assays for estimating <scp>HIV</scp> incidence: updated global market assessment and estimated economic value. Journal of the International AIDS Society, 2017, 20, e25018.	3.0	6
10	Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO) Tj ETQq0) O O11.g/BT /(Overkock 10 ⁻
11	Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO) Tj ETQq1	1 0178431	l4 r g& T /Over
12	Injectable Progestinâ€Only Contraception is Associated With Increased Levels of Proâ€Inflammatory Cytokines in the Female Genital Tract. American Journal of Reproductive Immunology, 2015, 74, 357-367.	1.2	63
13	Hormonal Contraception and the Risk of HIV Acquisition: An Individual Participant Data Meta-analysis. PLoS Medicine, 2015, 12, e1001778.	8.4	170
14	Comparison of Antibody Responses to HIV Infection in Ugandan Women Infected with HIV Subtypes A and D. AIDS Research and Human Retroviruses, 2015, 31, 421-427.	1.1	16
15	Development of Methods for Cross-Sectional HIV Incidence Estimation in a Large, Community Randomized Trial. PLoS ONE, 2013, 8, e78818.	2.5	33
16	Hormonal contraception and the risk of HIV acquisition among women in South Africa. Aids, 2012, 26, 497-504.	2.2	71
17	Hormonal Contraceptive Use and HIV Disease Progression Among Women in Uganda and Zimbabwe. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 157-164.	2.1	38
18	Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. Aids, 2010, 24, 1778-1781.	2.2	126

#	Article	IF	CITATIONS
19	Highly effective contraception and acquisition of HIV and other sexually transmitted infections. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2009, 23, 263-284.	2.8	80
20	Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. Aids, 2007, 21, 1515-1523.	2.2	91
21	Hormonal contraception and the risk of HIV acquisition. Aids, 2007, 21, 85-95.	2.2	180